Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of alterations. Patients ( = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prio...
Gespeichert in:
| Veröffentlicht in: | Cancer discovery 2018-07, Vol.8 (7), p.812-821 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 821 |
|---|---|
| container_issue | 7 |
| container_start_page | 812 |
| container_title | Cancer discovery |
| container_volume | 8 |
| creator | Pal, Sumanta K Rosenberg, Jonathan E Hoffman-Censits, Jean H Berger, Raanan Quinn, David I Galsky, Matthew D Wolf, Juergen Dittrich, Christian Keam, Bhumsuk Delord, Jean-Pierre Schellens, Jan H M Gravis, Gwenaelle Medioni, Jacques Maroto, Pablo Sriuranpong, Virote Charoentum, Chaiyut Burris, Howard A Grünwald, Viktor Petrylak, Daniel Vaishampayan, Ulka Gez, Eliahu De Giorgi, Ugo Lee, Jae-Lyun Voortman, Jens Gupta, Sumati Sharma, Sunil Mortazavi, Amir Vaughn, David J Isaacs, Randi Parker, Katie Chen, Xueying Yu, Kun Porter, Dale Graus Porta, Diana Bajorin, Dean F |
| description | BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of
alterations. Patients (
= 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted.
BJG398 is active in patients with alterations in
, resulting in both reductions in tumor volume and stabilization of disease. Our data highlight putative mechanisms of resistance to the agent, which may be useful in following disease status.
. |
| doi_str_mv | 10.1158/2159-8290.CD-18-0229 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6716598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2047920090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-8ed7d396485a807f2f0cf969d574a14ee42fccbd6ee50dbb82b213495b4422d83</originalsourceid><addsrcrecordid>eNpVUU1v3CAUtKpWTZTmH1QVxx7iFDDYcKm0deJtqkiNouSM-HjuUnnNFtiN9tf0r9bWJquGC_NgZuC9KYqPBF8SwsUXSrgsBZX4sr0qiSgxpfJNcXo8fnvEDTspzlP6jafFJOO4eV-cUCmYqDE_Lf5e97232u5R6NG35Y9KigukUedNDGbQKaNlDE95hTptc4joHixsZkDKCt2MK2_8VF0gP6I7nT2MOaEnP_HvIux82KZhjx4i6AwOLdxOj3YCjzHkFQxeD6jV0foxrPVB1S27-wothgxxcgtj-lC86_WQ4Px5Pyseu-uH9nt5-3N50y5uS8tIlUsBrnGVrJngWuCmpz22vayl4w3ThAEw2ltrXA3AsTNGUENJxSQ3jFHqRHVWfD34brZmDc5OjUQ9qE30ax33KmivXt-MfqV-hZ2qG1JzORt8fjaI4c8WUlZrnywMgx5hGoOimDWSYizxRGUHqo0hpQj98RmC1RyvmrNTc46qvVJEqDneSfbp_y8eRS9hVv8ATXuiTA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2047920090</pqid></control><display><type>article</type><title>Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>Pal, Sumanta K ; Rosenberg, Jonathan E ; Hoffman-Censits, Jean H ; Berger, Raanan ; Quinn, David I ; Galsky, Matthew D ; Wolf, Juergen ; Dittrich, Christian ; Keam, Bhumsuk ; Delord, Jean-Pierre ; Schellens, Jan H M ; Gravis, Gwenaelle ; Medioni, Jacques ; Maroto, Pablo ; Sriuranpong, Virote ; Charoentum, Chaiyut ; Burris, Howard A ; Grünwald, Viktor ; Petrylak, Daniel ; Vaishampayan, Ulka ; Gez, Eliahu ; De Giorgi, Ugo ; Lee, Jae-Lyun ; Voortman, Jens ; Gupta, Sumati ; Sharma, Sunil ; Mortazavi, Amir ; Vaughn, David J ; Isaacs, Randi ; Parker, Katie ; Chen, Xueying ; Yu, Kun ; Porter, Dale ; Graus Porta, Diana ; Bajorin, Dean F</creator><creatorcontrib>Pal, Sumanta K ; Rosenberg, Jonathan E ; Hoffman-Censits, Jean H ; Berger, Raanan ; Quinn, David I ; Galsky, Matthew D ; Wolf, Juergen ; Dittrich, Christian ; Keam, Bhumsuk ; Delord, Jean-Pierre ; Schellens, Jan H M ; Gravis, Gwenaelle ; Medioni, Jacques ; Maroto, Pablo ; Sriuranpong, Virote ; Charoentum, Chaiyut ; Burris, Howard A ; Grünwald, Viktor ; Petrylak, Daniel ; Vaishampayan, Ulka ; Gez, Eliahu ; De Giorgi, Ugo ; Lee, Jae-Lyun ; Voortman, Jens ; Gupta, Sumati ; Sharma, Sunil ; Mortazavi, Amir ; Vaughn, David J ; Isaacs, Randi ; Parker, Katie ; Chen, Xueying ; Yu, Kun ; Porter, Dale ; Graus Porta, Diana ; Bajorin, Dean F</creatorcontrib><description>BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of
alterations. Patients (
= 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted.
BJG398 is active in patients with alterations in
, resulting in both reductions in tumor volume and stabilization of disease. Our data highlight putative mechanisms of resistance to the agent, which may be useful in following disease status.
.</description><identifier>ISSN: 2159-8274</identifier><identifier>EISSN: 2159-8290</identifier><identifier>DOI: 10.1158/2159-8290.CD-18-0229</identifier><identifier>PMID: 29848605</identifier><language>eng</language><publisher>United States</publisher><subject>Administration, Oral ; Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Phenylurea Compounds - administration & dosage ; Phenylurea Compounds - adverse effects ; Phenylurea Compounds - pharmacology ; Phenylurea Compounds - therapeutic use ; Pyrimidines - administration & dosage ; Pyrimidines - adverse effects ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use ; Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors ; Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors ; Receptor, Fibroblast Growth Factor, Type 3 - genetics ; Treatment Outcome ; Urologic Neoplasms - drug therapy ; Urologic Neoplasms - metabolism</subject><ispartof>Cancer discovery, 2018-07, Vol.8 (7), p.812-821</ispartof><rights>2018 American Association for Cancer Research.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-8ed7d396485a807f2f0cf969d574a14ee42fccbd6ee50dbb82b213495b4422d83</citedby><cites>FETCH-LOGICAL-c413t-8ed7d396485a807f2f0cf969d574a14ee42fccbd6ee50dbb82b213495b4422d83</cites><orcidid>0000-0003-0433-8976 ; 0000-0001-7520-2908 ; 0000-0001-7305-5561 ; 0000-0003-2083-7687 ; 0000-0002-1411-0417</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,3343,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29848605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pal, Sumanta K</creatorcontrib><creatorcontrib>Rosenberg, Jonathan E</creatorcontrib><creatorcontrib>Hoffman-Censits, Jean H</creatorcontrib><creatorcontrib>Berger, Raanan</creatorcontrib><creatorcontrib>Quinn, David I</creatorcontrib><creatorcontrib>Galsky, Matthew D</creatorcontrib><creatorcontrib>Wolf, Juergen</creatorcontrib><creatorcontrib>Dittrich, Christian</creatorcontrib><creatorcontrib>Keam, Bhumsuk</creatorcontrib><creatorcontrib>Delord, Jean-Pierre</creatorcontrib><creatorcontrib>Schellens, Jan H M</creatorcontrib><creatorcontrib>Gravis, Gwenaelle</creatorcontrib><creatorcontrib>Medioni, Jacques</creatorcontrib><creatorcontrib>Maroto, Pablo</creatorcontrib><creatorcontrib>Sriuranpong, Virote</creatorcontrib><creatorcontrib>Charoentum, Chaiyut</creatorcontrib><creatorcontrib>Burris, Howard A</creatorcontrib><creatorcontrib>Grünwald, Viktor</creatorcontrib><creatorcontrib>Petrylak, Daniel</creatorcontrib><creatorcontrib>Vaishampayan, Ulka</creatorcontrib><creatorcontrib>Gez, Eliahu</creatorcontrib><creatorcontrib>De Giorgi, Ugo</creatorcontrib><creatorcontrib>Lee, Jae-Lyun</creatorcontrib><creatorcontrib>Voortman, Jens</creatorcontrib><creatorcontrib>Gupta, Sumati</creatorcontrib><creatorcontrib>Sharma, Sunil</creatorcontrib><creatorcontrib>Mortazavi, Amir</creatorcontrib><creatorcontrib>Vaughn, David J</creatorcontrib><creatorcontrib>Isaacs, Randi</creatorcontrib><creatorcontrib>Parker, Katie</creatorcontrib><creatorcontrib>Chen, Xueying</creatorcontrib><creatorcontrib>Yu, Kun</creatorcontrib><creatorcontrib>Porter, Dale</creatorcontrib><creatorcontrib>Graus Porta, Diana</creatorcontrib><creatorcontrib>Bajorin, Dean F</creatorcontrib><title>Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations</title><title>Cancer discovery</title><addtitle>Cancer Discov</addtitle><description>BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of
alterations. Patients (
= 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted.
BJG398 is active in patients with alterations in
, resulting in both reductions in tumor volume and stabilization of disease. Our data highlight putative mechanisms of resistance to the agent, which may be useful in following disease status.
.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Phenylurea Compounds - administration & dosage</subject><subject>Phenylurea Compounds - adverse effects</subject><subject>Phenylurea Compounds - pharmacology</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrimidines - therapeutic use</subject><subject>Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors</subject><subject>Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors</subject><subject>Receptor, Fibroblast Growth Factor, Type 3 - genetics</subject><subject>Treatment Outcome</subject><subject>Urologic Neoplasms - drug therapy</subject><subject>Urologic Neoplasms - metabolism</subject><issn>2159-8274</issn><issn>2159-8290</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUU1v3CAUtKpWTZTmH1QVxx7iFDDYcKm0deJtqkiNouSM-HjuUnnNFtiN9tf0r9bWJquGC_NgZuC9KYqPBF8SwsUXSrgsBZX4sr0qiSgxpfJNcXo8fnvEDTspzlP6jafFJOO4eV-cUCmYqDE_Lf5e97232u5R6NG35Y9KigukUedNDGbQKaNlDE95hTptc4joHixsZkDKCt2MK2_8VF0gP6I7nT2MOaEnP_HvIux82KZhjx4i6AwOLdxOj3YCjzHkFQxeD6jV0foxrPVB1S27-wothgxxcgtj-lC86_WQ4Px5Pyseu-uH9nt5-3N50y5uS8tIlUsBrnGVrJngWuCmpz22vayl4w3ThAEw2ltrXA3AsTNGUENJxSQ3jFHqRHVWfD34brZmDc5OjUQ9qE30ax33KmivXt-MfqV-hZ2qG1JzORt8fjaI4c8WUlZrnywMgx5hGoOimDWSYizxRGUHqo0hpQj98RmC1RyvmrNTc46qvVJEqDneSfbp_y8eRS9hVv8ATXuiTA</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Pal, Sumanta K</creator><creator>Rosenberg, Jonathan E</creator><creator>Hoffman-Censits, Jean H</creator><creator>Berger, Raanan</creator><creator>Quinn, David I</creator><creator>Galsky, Matthew D</creator><creator>Wolf, Juergen</creator><creator>Dittrich, Christian</creator><creator>Keam, Bhumsuk</creator><creator>Delord, Jean-Pierre</creator><creator>Schellens, Jan H M</creator><creator>Gravis, Gwenaelle</creator><creator>Medioni, Jacques</creator><creator>Maroto, Pablo</creator><creator>Sriuranpong, Virote</creator><creator>Charoentum, Chaiyut</creator><creator>Burris, Howard A</creator><creator>Grünwald, Viktor</creator><creator>Petrylak, Daniel</creator><creator>Vaishampayan, Ulka</creator><creator>Gez, Eliahu</creator><creator>De Giorgi, Ugo</creator><creator>Lee, Jae-Lyun</creator><creator>Voortman, Jens</creator><creator>Gupta, Sumati</creator><creator>Sharma, Sunil</creator><creator>Mortazavi, Amir</creator><creator>Vaughn, David J</creator><creator>Isaacs, Randi</creator><creator>Parker, Katie</creator><creator>Chen, Xueying</creator><creator>Yu, Kun</creator><creator>Porter, Dale</creator><creator>Graus Porta, Diana</creator><creator>Bajorin, Dean F</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0433-8976</orcidid><orcidid>https://orcid.org/0000-0001-7520-2908</orcidid><orcidid>https://orcid.org/0000-0001-7305-5561</orcidid><orcidid>https://orcid.org/0000-0003-2083-7687</orcidid><orcidid>https://orcid.org/0000-0002-1411-0417</orcidid></search><sort><creationdate>20180701</creationdate><title>Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations</title><author>Pal, Sumanta K ; Rosenberg, Jonathan E ; Hoffman-Censits, Jean H ; Berger, Raanan ; Quinn, David I ; Galsky, Matthew D ; Wolf, Juergen ; Dittrich, Christian ; Keam, Bhumsuk ; Delord, Jean-Pierre ; Schellens, Jan H M ; Gravis, Gwenaelle ; Medioni, Jacques ; Maroto, Pablo ; Sriuranpong, Virote ; Charoentum, Chaiyut ; Burris, Howard A ; Grünwald, Viktor ; Petrylak, Daniel ; Vaishampayan, Ulka ; Gez, Eliahu ; De Giorgi, Ugo ; Lee, Jae-Lyun ; Voortman, Jens ; Gupta, Sumati ; Sharma, Sunil ; Mortazavi, Amir ; Vaughn, David J ; Isaacs, Randi ; Parker, Katie ; Chen, Xueying ; Yu, Kun ; Porter, Dale ; Graus Porta, Diana ; Bajorin, Dean F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-8ed7d396485a807f2f0cf969d574a14ee42fccbd6ee50dbb82b213495b4422d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Phenylurea Compounds - administration & dosage</topic><topic>Phenylurea Compounds - adverse effects</topic><topic>Phenylurea Compounds - pharmacology</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrimidines - therapeutic use</topic><topic>Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors</topic><topic>Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors</topic><topic>Receptor, Fibroblast Growth Factor, Type 3 - genetics</topic><topic>Treatment Outcome</topic><topic>Urologic Neoplasms - drug therapy</topic><topic>Urologic Neoplasms - metabolism</topic><toplevel>online_resources</toplevel><creatorcontrib>Pal, Sumanta K</creatorcontrib><creatorcontrib>Rosenberg, Jonathan E</creatorcontrib><creatorcontrib>Hoffman-Censits, Jean H</creatorcontrib><creatorcontrib>Berger, Raanan</creatorcontrib><creatorcontrib>Quinn, David I</creatorcontrib><creatorcontrib>Galsky, Matthew D</creatorcontrib><creatorcontrib>Wolf, Juergen</creatorcontrib><creatorcontrib>Dittrich, Christian</creatorcontrib><creatorcontrib>Keam, Bhumsuk</creatorcontrib><creatorcontrib>Delord, Jean-Pierre</creatorcontrib><creatorcontrib>Schellens, Jan H M</creatorcontrib><creatorcontrib>Gravis, Gwenaelle</creatorcontrib><creatorcontrib>Medioni, Jacques</creatorcontrib><creatorcontrib>Maroto, Pablo</creatorcontrib><creatorcontrib>Sriuranpong, Virote</creatorcontrib><creatorcontrib>Charoentum, Chaiyut</creatorcontrib><creatorcontrib>Burris, Howard A</creatorcontrib><creatorcontrib>Grünwald, Viktor</creatorcontrib><creatorcontrib>Petrylak, Daniel</creatorcontrib><creatorcontrib>Vaishampayan, Ulka</creatorcontrib><creatorcontrib>Gez, Eliahu</creatorcontrib><creatorcontrib>De Giorgi, Ugo</creatorcontrib><creatorcontrib>Lee, Jae-Lyun</creatorcontrib><creatorcontrib>Voortman, Jens</creatorcontrib><creatorcontrib>Gupta, Sumati</creatorcontrib><creatorcontrib>Sharma, Sunil</creatorcontrib><creatorcontrib>Mortazavi, Amir</creatorcontrib><creatorcontrib>Vaughn, David J</creatorcontrib><creatorcontrib>Isaacs, Randi</creatorcontrib><creatorcontrib>Parker, Katie</creatorcontrib><creatorcontrib>Chen, Xueying</creatorcontrib><creatorcontrib>Yu, Kun</creatorcontrib><creatorcontrib>Porter, Dale</creatorcontrib><creatorcontrib>Graus Porta, Diana</creatorcontrib><creatorcontrib>Bajorin, Dean F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pal, Sumanta K</au><au>Rosenberg, Jonathan E</au><au>Hoffman-Censits, Jean H</au><au>Berger, Raanan</au><au>Quinn, David I</au><au>Galsky, Matthew D</au><au>Wolf, Juergen</au><au>Dittrich, Christian</au><au>Keam, Bhumsuk</au><au>Delord, Jean-Pierre</au><au>Schellens, Jan H M</au><au>Gravis, Gwenaelle</au><au>Medioni, Jacques</au><au>Maroto, Pablo</au><au>Sriuranpong, Virote</au><au>Charoentum, Chaiyut</au><au>Burris, Howard A</au><au>Grünwald, Viktor</au><au>Petrylak, Daniel</au><au>Vaishampayan, Ulka</au><au>Gez, Eliahu</au><au>De Giorgi, Ugo</au><au>Lee, Jae-Lyun</au><au>Voortman, Jens</au><au>Gupta, Sumati</au><au>Sharma, Sunil</au><au>Mortazavi, Amir</au><au>Vaughn, David J</au><au>Isaacs, Randi</au><au>Parker, Katie</au><au>Chen, Xueying</au><au>Yu, Kun</au><au>Porter, Dale</au><au>Graus Porta, Diana</au><au>Bajorin, Dean F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations</atitle><jtitle>Cancer discovery</jtitle><addtitle>Cancer Discov</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>8</volume><issue>7</issue><spage>812</spage><epage>821</epage><pages>812-821</pages><issn>2159-8274</issn><eissn>2159-8290</eissn><abstract>BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of
alterations. Patients (
= 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted.
BJG398 is active in patients with alterations in
, resulting in both reductions in tumor volume and stabilization of disease. Our data highlight putative mechanisms of resistance to the agent, which may be useful in following disease status.
.</abstract><cop>United States</cop><pmid>29848605</pmid><doi>10.1158/2159-8290.CD-18-0229</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0433-8976</orcidid><orcidid>https://orcid.org/0000-0001-7520-2908</orcidid><orcidid>https://orcid.org/0000-0001-7305-5561</orcidid><orcidid>https://orcid.org/0000-0003-2083-7687</orcidid><orcidid>https://orcid.org/0000-0002-1411-0417</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2159-8274 |
| ispartof | Cancer discovery, 2018-07, Vol.8 (7), p.812-821 |
| issn | 2159-8274 2159-8290 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6716598 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research |
| subjects | Administration, Oral Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Female Humans Male Middle Aged Mutation Phenylurea Compounds - administration & dosage Phenylurea Compounds - adverse effects Phenylurea Compounds - pharmacology Phenylurea Compounds - therapeutic use Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - pharmacology Pyrimidines - therapeutic use Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 3 - genetics Treatment Outcome Urologic Neoplasms - drug therapy Urologic Neoplasms - metabolism |
| title | Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A51%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20BGJ398,%20a%20Fibroblast%20Growth%20Factor%20Receptor%201-3%20Inhibitor,%20in%20Patients%20with%20Previously%20Treated%20Advanced%20Urothelial%20Carcinoma%20with%20FGFR3%20Alterations&rft.jtitle=Cancer%20discovery&rft.au=Pal,%20Sumanta%20K&rft.date=2018-07-01&rft.volume=8&rft.issue=7&rft.spage=812&rft.epage=821&rft.pages=812-821&rft.issn=2159-8274&rft.eissn=2159-8290&rft_id=info:doi/10.1158/2159-8290.CD-18-0229&rft_dat=%3Cproquest_pubme%3E2047920090%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2047920090&rft_id=info:pmid/29848605&rfr_iscdi=true |